MX2017016851A - Anticuerpo para el ligando del factor 1 de muerte celular programada (pdl-1), composicion farmaceutica del mismo y uso de los mismos. - Google Patents
Anticuerpo para el ligando del factor 1 de muerte celular programada (pdl-1), composicion farmaceutica del mismo y uso de los mismos.Info
- Publication number
- MX2017016851A MX2017016851A MX2017016851A MX2017016851A MX2017016851A MX 2017016851 A MX2017016851 A MX 2017016851A MX 2017016851 A MX2017016851 A MX 2017016851A MX 2017016851 A MX2017016851 A MX 2017016851A MX 2017016851 A MX2017016851 A MX 2017016851A
- Authority
- MX
- Mexico
- Prior art keywords
- pdl
- antibody
- pharmaceutical composition
- clone antibody
- clone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57411—Specifically defined cancers of cervix
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Abstract
Se provee un anticuerpo monoclonal para el ligando del factor 1 de muerte celular programada (PDL-1) o un segmento de combinación antigénica. El anticuerpo monoclonal se puede combinar específicamente con el PDL-1, elimina la inhibición de PDL-1 sobre la inmunidad del cuerpo, de modo que se activan los linfocitos T. También se provee una composición farmacéutica que comprende el anticuerpo monoclonal y los usos de la misma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610122117 | 2016-03-04 | ||
PCT/CN2017/075484 WO2017148424A1 (zh) | 2016-03-04 | 2017-03-02 | 一种pdl-1抗体、其药物组合物及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017016851A true MX2017016851A (es) | 2018-04-30 |
Family
ID=59742540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017016851A MX2017016851A (es) | 2016-03-04 | 2017-03-02 | Anticuerpo para el ligando del factor 1 de muerte celular programada (pdl-1), composicion farmaceutica del mismo y uso de los mismos. |
Country Status (13)
Country | Link |
---|---|
US (2) | US10465014B2 (es) |
EP (1) | EP3309177B1 (es) |
JP (1) | JP6432121B2 (es) |
KR (1) | KR102068600B1 (es) |
CN (3) | CN107151269B (es) |
AU (1) | AU2017226510C1 (es) |
BR (1) | BR112017027877A2 (es) |
CA (1) | CA2987118C (es) |
ES (1) | ES2801873T3 (es) |
HK (2) | HK1247209A1 (es) |
MX (1) | MX2017016851A (es) |
RU (1) | RU2693661C2 (es) |
WO (1) | WO2017148424A1 (es) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
IL292449B2 (en) | 2015-03-13 | 2024-02-01 | Cytomx Therapeutics Inc | Nucleic acids encoding antibodies against PDL1 and methods for their preparation |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
KR20200016899A (ko) | 2017-06-01 | 2020-02-17 | 싸이톰스 테라퓨틱스, 인크. | 활성화가능 항-pdl1 항체, 및 이의 이용 방법 |
US11266674B2 (en) | 2017-09-01 | 2022-03-08 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Pharmaceutical composition for tumor treatment or prevention, method, and use thereof |
WO2019109974A1 (zh) * | 2017-12-06 | 2019-06-13 | 正大天晴药业集团南京顺欣制药有限公司 | 抗pd-l1抗体及其抗原结合片段 |
CN107973854B (zh) * | 2017-12-11 | 2021-05-04 | 苏州银河生物医药有限公司 | Pdl1单克隆抗体及其应用 |
TW201930350A (zh) * | 2017-12-28 | 2019-08-01 | 大陸商南京傳奇生物科技有限公司 | 針對pd-l1之抗體及其變異體 |
CN108250296B (zh) * | 2018-01-17 | 2020-07-07 | 长春金赛药业有限责任公司 | 全人源抗人pd-l1单克隆抗体及其应用 |
CN108276492B (zh) * | 2018-01-31 | 2021-12-14 | 中国药科大学 | 抗pd-l1单克隆抗体及其应用 |
CN108314734B (zh) * | 2018-01-31 | 2021-11-05 | 中国药科大学 | 抗pd-1单克隆抗体及其应用 |
CR20200465A (es) * | 2018-03-13 | 2020-11-17 | Tust Therapeutics Ltd | Agentes anticuerpos anti-cd25 |
EP3770262A4 (en) * | 2018-03-16 | 2021-12-15 | National University Corporation Shiga University of Medical Science | ANTIBODY FRAGMENT DEGRADING AND ELIMINATING ABNORMAL TDP-43 |
WO2019227490A1 (en) * | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
BR112020023505A2 (pt) * | 2018-06-01 | 2021-03-30 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Composições e usos das mesmas para tratamento de doença ou condição |
EP3819313A4 (en) * | 2018-07-03 | 2021-09-01 | L&L Biopharma Co., Ltd. | BISPECIFIC ANTIBODIES AND ITS USE |
CN108948205B (zh) * | 2018-07-13 | 2021-09-28 | 北京金岱生物科技有限公司 | 抗idh1r132h单克隆抗体及其应用 |
TWI822815B (zh) * | 2018-07-14 | 2023-11-21 | 財團法人生物技術開發中心 | 抗-人類pd-l1之抗體及其用途 |
CN110734493B (zh) * | 2018-07-20 | 2021-12-17 | 厦门大学 | 抗pd-1抗体及其用途 |
CN112638415A (zh) * | 2018-07-26 | 2021-04-09 | 大有华夏生物医药集团有限公司 | 用于成像的组合物和方法 |
HUE062320T2 (hu) * | 2018-07-31 | 2023-10-28 | Pieris Pharmaceuticals Gmbh | CD137-re és PD-L1-re specifikus új fúziós fehérje |
CN109232740B (zh) * | 2018-08-20 | 2022-05-10 | 中国科学院微生物研究所 | 一种抗pd-l1抗体及其在抗肿瘤治疗中的应用 |
EP3843849A1 (en) | 2018-08-27 | 2021-07-07 | Pieris Pharmaceuticals GmbH | Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof |
CN110878122B (zh) * | 2018-09-06 | 2023-07-28 | 上海张江生物技术有限公司 | 重组抗pd-l1单克隆抗体 |
CN108997500B (zh) * | 2018-09-12 | 2020-08-21 | 首都医科大学附属北京胸科医院 | 一种抗人pd-l1抗体及其应用 |
CN108997499B (zh) * | 2018-09-12 | 2020-07-31 | 首都医科大学附属北京胸科医院 | 一种抗人pd-l1抗体及其应用 |
CN114957475B (zh) * | 2018-09-26 | 2023-06-20 | 福州拓新天成生物科技有限公司 | 抗b7-h3的单克隆抗体及其在细胞治疗中的应用 |
CN112672759B (zh) * | 2018-09-29 | 2023-05-30 | 四川科伦博泰生物医药股份有限公司 | 抗程序性死亡配体-1(pd-l1)抗体的抗肿瘤用途 |
TW202020159A (zh) * | 2018-11-16 | 2020-06-01 | 大陸商南京金斯瑞生物科技有限公司 | 人源化抗人pd-l1單克隆抗體及其製備方法和用途 |
CN111234017B (zh) * | 2018-11-28 | 2022-09-09 | 优迈生物科技(连云港)有限公司 | 一种抗人pd-l1抗体及其抗原结合片段、制备方法和应用 |
WO2020108497A1 (zh) | 2018-11-29 | 2020-06-04 | 和铂医药(香港)有限公司 | 一种抗pd-l1抗体制剂 |
CN111363040B (zh) * | 2018-12-25 | 2023-07-14 | 杭州翰思生物医药有限公司 | 抗ox40的单克隆抗体及其应用 |
CN113795511A (zh) * | 2019-01-23 | 2021-12-14 | 大有华夏生物医药集团有限公司 | 抗pd-l1双抗体及其用途 |
AU2020213579A1 (en) * | 2019-02-03 | 2021-09-02 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof |
EP3929213A4 (en) * | 2019-02-21 | 2023-03-08 | Eucure (Beijing) Biopharma Co., Ltd | ANTI-PD-L1 ANTIBODIES AND ITS USE |
CN109929037B (zh) * | 2019-04-01 | 2023-03-17 | 华博生物医药技术(上海)有限公司 | 针对程序性死亡配体的结合物及其应用 |
CN111606995B (zh) * | 2019-06-04 | 2021-02-12 | 优睿赛思(武汉)生物科技有限公司 | 抗人pd-l1单克隆抗体及其应用 |
MX2022001321A (es) * | 2019-08-02 | 2022-05-20 | Akeso Pharmaceuticals Inc | Anticuerpo biespecifico anti-ctla4/anti-pd-1 y uso del mismo. |
EP4008351A4 (en) | 2019-08-02 | 2023-08-09 | CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. | ANTI-PD-1 ANTIBODIES AND ASSOCIATED MEDICAL USE |
EP4034568A4 (en) | 2019-09-25 | 2024-02-14 | Wuxi Biologics Ireland Ltd | NOVEL ANTI-PD-L1 ANTIBODIES |
CN110478472B (zh) * | 2019-09-29 | 2020-08-28 | 北京鼎成肽源生物技术有限公司 | Pd-1封闭剂及其应用 |
CN110903391B (zh) * | 2019-10-25 | 2021-05-28 | 东大生物技术(苏州)有限公司 | 一组pd-l1单克隆抗体及其医药用途 |
JP2023500156A (ja) * | 2019-11-08 | 2023-01-04 | チャンスー シムサー ファーマシューティカル カンパニー リミテッド | 抗-ヒトプログラム細胞死リガンド-1(pd-l1)の抗体及びその用途 |
JP2023504003A (ja) * | 2019-11-25 | 2023-02-01 | 中山康方生物医▲藥▼有限公司 | 抗pd-1-抗vegfa二重特異性抗体、その医薬組成物および使用 |
CN113372445B (zh) * | 2020-03-10 | 2023-09-12 | 鲁南制药集团股份有限公司 | 一种抗pd-1单克隆抗体 |
CN113842456B (zh) * | 2020-06-28 | 2022-07-26 | 上海齐鲁制药研究中心有限公司 | 一种抗人4-1bb的单克隆抗体制剂及其用途 |
CN114456267B (zh) * | 2020-11-03 | 2023-12-01 | 浙江大学医学院附属第二医院 | 一种抗cd73人源化单克隆抗体及其应用 |
CN112500486B (zh) * | 2020-12-02 | 2023-05-05 | 杭州百凌生物科技有限公司 | 一种抗pd-l1抗体及其应用 |
WO2022121846A1 (zh) * | 2020-12-08 | 2022-06-16 | 博际生物医药科技(杭州)有限公司 | Pd-l1抗体及其应用 |
CN114316047B (zh) * | 2021-01-14 | 2023-12-22 | 东大生物技术(苏州)有限公司 | 一组pd-1单克隆抗体及其医药用途 |
CN115521379B (zh) * | 2021-07-16 | 2023-12-22 | 南京吉盛澳玛生物医药有限公司 | Pd-1抗体及其用途 |
WO2023134706A1 (zh) * | 2022-01-13 | 2023-07-20 | 四川科伦博泰生物医药股份有限公司 | 抗trop-2抗体偶联药物和其他治疗剂的组合用途 |
CN117186223A (zh) * | 2022-05-31 | 2023-12-08 | 明济生物制药(北京)有限公司 | 抗pd-l1抗体及编码其的核酸、制备方法和应用 |
CN115925937A (zh) * | 2022-08-05 | 2023-04-07 | 赛灵药业科技集团股份有限公司北京分公司 | 一种抗体或其片段及其制药用途 |
CN117679505A (zh) * | 2022-09-09 | 2024-03-12 | 中山康方生物医药有限公司 | 药物组合及用途 |
CN115785269B (zh) * | 2022-11-01 | 2023-09-22 | 四川大学 | 抗pd-l1的抗体及其应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
CN101104640A (zh) * | 2006-07-10 | 2008-01-16 | 苏州大学 | 抗人pd-l1单克隆抗体制备及应用 |
NZ629273A (en) | 2006-12-27 | 2015-02-27 | Harvard College | Compositions and methods for the treatment of infections and tumors |
WO2009114335A2 (en) * | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제 |
SG196798A1 (en) | 2008-12-09 | 2014-02-13 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
WO2010102278A1 (en) | 2009-03-06 | 2010-09-10 | President And Fellows Of Harvard College | Methods and compositions for the generation and maintenance of regulatory t cells |
ES2641612T3 (es) | 2009-04-17 | 2017-11-10 | Immunas Pharma, Inc. | Anticuerpos que se unen específicamente a oligómeros de beta A y uso de los mismos |
CA2778714C (en) * | 2009-11-24 | 2018-02-27 | Medimmune Limited | Targeted binding agents against b7-h1 |
US8557777B2 (en) * | 2010-07-09 | 2013-10-15 | The Board Of Trustees Of The University Of Illinois | Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides |
PT2785375T (pt) | 2011-11-28 | 2020-10-29 | Merck Patent Gmbh | Anticorpos anti-pd-l1 e usos destes |
SG10201700698WA (en) * | 2012-05-15 | 2017-02-27 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
EP2854843A4 (en) | 2012-05-31 | 2016-06-01 | Sorrento Therapeutics Inc | ANTIGEN BINDING PROTEINS THAT BIND PD-L1 |
CN105175537B (zh) * | 2012-06-08 | 2019-03-05 | 厦门大学 | 抗hpv l1蛋白的广谱单克隆抗体或其抗原结合片段及它们的用途 |
US9845356B2 (en) * | 2012-08-03 | 2017-12-19 | Dana-Farber Cancer Institute, Inc. | Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use |
WO2014055897A2 (en) | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
KR20230070054A (ko) | 2013-03-15 | 2023-05-19 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
CN103242448B (zh) * | 2013-05-27 | 2015-01-14 | 郑州大学 | 一种全人源化抗pd-1单克隆抗体及其制备方法和应用 |
CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
CN104558177B (zh) * | 2013-10-25 | 2020-02-18 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途 |
TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
JP6666905B2 (ja) | 2014-05-29 | 2020-03-18 | スプリング バイオサイエンス コーポレーション | Pd−l1抗体及びその使用 |
WO2015195163A1 (en) * | 2014-06-20 | 2015-12-23 | R-Pharm Overseas, Inc. | Pd-l1 antagonist fully human antibody |
KR102130600B1 (ko) | 2014-07-03 | 2020-07-08 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
CA2954868C (en) * | 2014-07-11 | 2023-08-29 | Genentech, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
CN104673895B (zh) * | 2015-01-21 | 2017-01-04 | 浙江理工大学 | 快速检测单增李斯特菌的分子标记 |
CN104673897B (zh) * | 2015-01-26 | 2017-09-29 | 江苏先声药业有限公司 | 一种测定pd‑1通路抑制剂之生物学活性的方法 |
CN105175544B (zh) * | 2015-10-20 | 2021-04-09 | 安徽瀚海博兴生物技术有限公司 | 一种抗pd-1人源化单克隆抗体及其应用 |
-
2017
- 2017-03-02 EP EP17759275.5A patent/EP3309177B1/en active Active
- 2017-03-02 ES ES17759275T patent/ES2801873T3/es active Active
- 2017-03-02 MX MX2017016851A patent/MX2017016851A/es unknown
- 2017-03-02 CN CN201710120847.7A patent/CN107151269B/zh active Active
- 2017-03-02 RU RU2017145150A patent/RU2693661C2/ru active
- 2017-03-02 KR KR1020177036591A patent/KR102068600B1/ko active IP Right Grant
- 2017-03-02 CN CN201810647974.7A patent/CN108752476B/zh active Active
- 2017-03-02 BR BR112017027877-4A patent/BR112017027877A2/pt active Search and Examination
- 2017-03-02 US US15/745,230 patent/US10465014B2/en active Active
- 2017-03-02 CN CN201780002182.8A patent/CN107922503B/zh active Active
- 2017-03-02 AU AU2017226510A patent/AU2017226510C1/en active Active
- 2017-03-02 CA CA2987118A patent/CA2987118C/en active Active
- 2017-03-02 JP JP2017565750A patent/JP6432121B2/ja active Active
- 2017-03-02 WO PCT/CN2017/075484 patent/WO2017148424A1/zh active Application Filing
-
2018
- 2018-05-10 HK HK18106097.9A patent/HK1247209A1/zh unknown
- 2018-05-23 HK HK18106688.4A patent/HK1247214B/zh unknown
-
2019
- 2019-07-19 US US16/516,991 patent/US11136413B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2017226510C1 (en) | 2019-05-16 |
HK1247209A1 (zh) | 2018-09-21 |
CA2987118C (en) | 2020-03-24 |
JP6432121B2 (ja) | 2018-12-05 |
KR20180004277A (ko) | 2018-01-10 |
KR102068600B1 (ko) | 2020-01-21 |
CA2987118A1 (en) | 2017-09-08 |
CN107922503B (zh) | 2018-08-28 |
US11136413B2 (en) | 2021-10-05 |
AU2017226510B2 (en) | 2019-01-17 |
ES2801873T3 (es) | 2021-01-14 |
JP2018526974A (ja) | 2018-09-20 |
RU2017145150A3 (es) | 2019-06-21 |
HK1247214B (zh) | 2019-07-19 |
CN107151269B (zh) | 2021-07-27 |
EP3309177B1 (en) | 2020-05-13 |
AU2017226510A1 (en) | 2018-01-04 |
US20180305464A1 (en) | 2018-10-25 |
CN108752476B (zh) | 2019-09-20 |
BR112017027877A2 (pt) | 2018-09-11 |
RU2693661C2 (ru) | 2019-07-03 |
US10465014B2 (en) | 2019-11-05 |
US20200010570A1 (en) | 2020-01-09 |
RU2017145150A (ru) | 2019-06-21 |
EP3309177A4 (en) | 2018-10-10 |
CN108752476A (zh) | 2018-11-06 |
WO2017148424A1 (zh) | 2017-09-08 |
CN107151269A (zh) | 2017-09-12 |
EP3309177A1 (en) | 2018-04-18 |
CN107922503A (zh) | 2018-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017016851A (es) | Anticuerpo para el ligando del factor 1 de muerte celular programada (pdl-1), composicion farmaceutica del mismo y uso de los mismos. | |
IL276830A (en) | Anti-claudin 18.2 antibodies and uses thereof | |
SG10202111141WA (en) | Anti-claudin 18.2 antibodies and uses thereof | |
EP3878863A4 (en) | ANTI-CLAUDIN18.2 ANTIBODIES AND ITS USE | |
MX2021013586A (es) | Anticuerpo monoclonal anti-antigeno 4 asociado a linfocitos t citotoxicos (ctla4) o su fragmento de union a antigeno, una composicion farmaceutica y uso. | |
EA201692222A1 (ru) | Искусственный клапан и спосб его изготовления | |
JP1644695S (ja) | 自動車 | |
ZA202103061B (en) | Anti-cldn18.2 antibody and uses thereof | |
BR112017000497A2 (pt) | ?anticorpos anti pd-l1 e usos de diagnóstico dos mesmos? | |
JP1644696S (ja) | 自動車 | |
MX2018013762A (es) | Polipeptidos de fusion de ligando de cumulo de diferenciacion 40 y fragmento cristalizable (cd40l-fc) y sus metodos de uso. | |
MX2016014837A (es) | Cierre de seguridad. | |
DK3528620T3 (da) | Akvakultursystem på åbent hav samt fremgangsmåde | |
JP1644697S (ja) | 自動車 | |
MX2020002070A (es) | Receptores solubles de interferon y usos de los mismos. | |
PH12020550930A1 (en) | Human igg fc domain variants with improved effector function | |
EP3645044A4 (en) | USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, ELEMENT A5 ANTIBODIES TO TREAT GLAUCOMA | |
TWD215713S (zh) | 呼吸治療系統流體收集器之封蓋 | |
JP1644692S (ja) | 自動車 | |
TWD189728S (zh) | 漂浮裝置之部分(二) | |
EP3692171A4 (en) | USING ANTI-FAMILY WITH SEQUENCE LIKE 19, ELEMENT A5 ANTIBODIES FOR TREATMENT AND DIAGNOSIS OF MENTAL DISORDERS | |
SE1750442A1 (sv) | Package and system for powder used in additive manufacturing | |
CO2020016479A2 (es) | Anticuerpos para un ligando 1 de muerte programada (pd-l1) y su aplicación | |
JP1645974S (ja) | 自動車 | |
BR112018015108A2 (pt) | módulo de correia transportadora magnética |